Back to search results

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

Abroad (travel likely)Recruiting

Conditions

Relapsing Multiple Sclerosis (RMS)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Novartis Investigative Site, Athens, Attica, Greece

  • Novartis Investigative Site, Athens, GR, Greece

  • Novartis Investigative Site, Alexandroupoli, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Chaïdári, Greece

  • Novartis Investigative Site, Crete Heraklion, Greece

  • Novartis Investigative Site, Ioannina, Greece

  • Novartis Investigative Site, Larissa, Greece

  • Novartis Investigative Site, Pátrai, Greece

  • Novartis Investigative Site, Thessaloniki, Greece

  • Novartis Investigative Site, Thessaloniki, Greece

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)